Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need

catecholamines
cyclophosphamide
carboplatin
mycn protein
doxorubicin
  • 273 views
  • 13 Oct, 2022
  • 115 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive

conventional surgery
carboplatin
mycn protein
thiotepa
melphalan
  • 117 views
  • 08 Apr, 2023
  • 106 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up

high-risk neuroblastoma
colony stimulating factor
bone marrow procedure
hu3f8
monoclonal antibodies
  • 159 views
  • 07 Oct, 2022
  • 23 locations
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to treatment (refractory). Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop …

bone marrow disease
neutrophil count
monoclonal antibodies
bone marrow procedure
tumor cells
  • 217 views
  • 14 Oct, 2022
  • 83 locations
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012)

Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients experience

platelet count
high-risk neuroblastoma
iobenguane
metastasis
bone marrow procedure
  • 17 views
  • 25 Feb, 2022
  • 8 locations
  • 0 views
  • 07 Oct, 2022
  • 1 location
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of

high-risk neuroblastoma
stem cell infusion
filgrastim
cyclophosphamide
carboplatin
  • 10 views
  • 23 Feb, 2022
  • 1 location
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL) (OPTIMUM)

The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma

neutrophil count
carboplatin
iobenguane
ejection fraction
melphalan
  • 58 views
  • 25 Oct, 2022
  • 20 locations
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

high-risk neuroblastoma
refractory neuroblastoma
renal function
platelet count
neutrophil count
  • 0 views
  • 07 Apr, 2023
  • 6 locations
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.

stem cell infusion
filgrastim
tretinoin
neutrophil count
carboplatin
  • 5 views
  • 06 Apr, 2023
  • 1 location